Shots:

• The company has completed the enrolment in the P-III HELIOS-B study evaluates the efficacy and safety of vutrisiran (25 mg- SC- q3M- for ~ 36 mos.) vs PBO in 600 patients in a ratio (1:1) with ATTR amyloidosis with cardiomyopathy across 123 activated sites in 32 countries
• The 1EP of the study is to evaluate the efficacy of vutrisiran on the composite EPs of all-cause mortality and recurrent CV events @30mos. The results are expected in early 2024
• Vutrisiran is an investigational RNAi therapeutic. Additionally- the company has completed the enrollment of APOLLO-B study in Jun’21 with its expected results in mid-2022

  | Ref: Businesswire | Image: Alnylam